Related Experiment Video
Updated: Jun 7, 2026

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins
Published on: June 11, 2015
First experimentally characterised Proteus phage endolysins have distinct metal cofactor dependencies
Akash Shambharkar1, Thomas P Thompson1, Laura A McClenaghan1
1School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, BT9 7BL, UK.
Abstract:
Proteus mirabilis is a Gram-negative uropathogenic bacterial species responsible for many catheter-associated urinary tract infections (CAUTIs). Due to the growing rates of antimicrobial resistance among CAUTI pathogens, novel antimicrobial solutions are urgently needed. Bacteriophage endolysins are an emerging class of antimicrobial agents, but no endolysins from P. mirabilis phages have been reported to date. Here, we describe two new Proteus phage endolysins, LysPM1 and LysPM2, containing Peptidase_M15_3 and CHAP domains, respectively. We experimentally confirmed their antibacterial activity against several Proteus spp. when used in combination with outer membrane permeabilizers, including EDTA, citric acid, and chloroform, as well as against frozen bacteria. Both enzymes have optimum activity at pH 7-8 and retain activity at temperatures up to 60 °C. Both endolysins completely lost their lytic activity upon treatment with EDTA, suggesting that divalent cations participate in the catalytic mechanism; the addition of Ca2⁺ and Zn2⁺ to LysPM1, and Ca2⁺ and Mn2⁺ to LysPM2 partially restored the activity. Our study confirms LysPM1 and LysPM2 as the first experimentally characterized Proteus phage endolysins, with LysPM2 also being the first experimentally characterized Gram-negative endolysin with a single CHAP domain. These findings could guide further development of phage-derived lytic enzymes for treatment of Proteus infections. KEY POINTS: • LysPM1 & LysPM2 are the first experimentally characterized Proteus phage endolysins. • Both are single-domain endolysins: Peptidase_M15_3 in LysPM1 and CHAP in LysPM2. • Metal cofactors are required for their activity: Zn2⁺ for LysPM1, Ca2⁺ for LysPM2.
Insights
Two novel Proteus phage endolysins, LysPM1 and LysPM2, show antibacterial activity against Proteus species. These findings offer new phage-derived antimicrobial solutions for treating urinary tract infections caused by these resilient bacteria.
Area of Science:
- Microbiology
- Biochemistry
- Molecular Biology
Background:
- Proteus mirabilis causes catheter-associated urinary tract infections (CAUTIs).
- Antimicrobial resistance in CAUTI pathogens necessitates novel treatments.
- Bacteriophage endolysins are promising antimicrobial agents, but none were previously characterized for Proteus.
Purpose of the Study:
- To identify and characterize novel bacteriophage endolysins from Proteus phages.
- To evaluate the antibacterial activity and optimal conditions for these endolysins.
- To investigate the role of metal cofactors in endolysin activity.
Main Methods:
- Isolation and characterization of two Proteus phage endolysins, LysPM1 and LysPM2.
- Experimental confirmation of antibacterial activity against Proteus species.
- Assessment of enzyme activity under varying pH, temperature, and in the presence of permeabilizers and metal ions.
Main Results:
- LysPM1 and LysPM2 are the first characterized endolysins from Proteus phages.
- Both enzymes exhibit antibacterial activity, particularly with outer membrane permeabilizers.
- Optimal activity is observed at pH 7-8 and up to 60°C, with metal cofactors (Zn2+ for LysPM1, Ca2+ for LysPM2) being essential.
Conclusions:
- LysPM1 and LysPM2 represent a new class of antibacterial agents against Proteus.
- LysPM2 is the first characterized single-domain CHAP endolysin active against Gram-negative bacteria.
- These endolysins hold potential for developing new therapies against Proteus infections.
Related Concept Videos
Lysogenic Cycle of Bacteriophages
Viral Replication: Lytic Cycle
